Nasal inflammation in sleep apnoea patients using CPAP and effect of heated humidification

Eur Respir J. 2011 Mar;37(3):587-94. doi: 10.1183/09031936.00036910. Epub 2010 Jul 1.

Abstract

Nasal continuous positive airway pressure (CPAP) can cause undesirable nasal symptoms, such as congestion to obstructive sleep apnoea (OSA) patients, whose symptoms can be attenuated by the addition of heated humidification. However, neither the nature of nasal symptoms nor the effect of heated humidification on nasal pathophysiology and pathology are convincingly known. 20 patients with OSA on nasal CPAP who exhibited symptomatic nasal obstruction were randomised to receive either 3 weeks of CPAP treatment with heated humidification or 3 weeks of CPAP treatment with sham-heated humidification, followed by 3 weeks of the opposite treatment, respectively. Nasal symptom score, nasal resistance, nasal lavage interleukin-6, interleukin-12 and tumour necrosis factor-α and nasal mucosa histopathology were assessed at baseline and after each treatment arm. Heated humidification in comparison with sham-heated humidification was associated with decrease in nasal symptomatology, resistance and lavage cytokines, and attenuation of inflammatory cell infiltration and fibrosis of the nasal mucosa. In conclusion, nasal obstruction of OSA patients on CPAP treatment is inflammatory in origin and the addition of heated humidification decreases nasal resistance and mucosal inflammation.

Trial registration: ClinicalTrials.gov NCT00850876.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biopsy
  • Continuous Positive Airway Pressure / methods*
  • Female
  • Humans
  • Humidity
  • Inflammation*
  • Interleukin-12 / blood
  • Interleukin-6 / biosynthesis
  • Male
  • Middle Aged
  • Mucous Membrane / pathology
  • Nasal Obstruction
  • Nose / pathology
  • Sleep Apnea, Obstructive / therapy*
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Interleukin-12

Associated data

  • ClinicalTrials.gov/NCT00850876